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Abstract 
 
Enterococci are the causative agents of several serious infections. In addition, antibiotic-
resistant enterococci are becoming increasingly prevalent due to the extensive use of 
antibiotics in the community and in hospitals. In this context, new antimicrobials acting by 
different mechanisms are highly desired. Lysins are bacteriophage-derived molecules that are 
produced when the bacteriophage (or phage) progeny needs to escape the bacterial host. 
Lysins very rapidly lyse the bacterial peptidoglycan. They can reach their target when added 
exogenously to Gram-positive bacteria, thanks to the lack of an impermeable outer membrane. 
In contrast, they are inactive when added externally to Gram-negative bacteria, which are 
surrounded by bilayer outer membrane. The action of lysins is normally restricted to bacterial 
hosts of the phages from which they were isolated, but some lysins have a broader spectrum 
of activity. In the present work, new lysins with a potentially lytic action against enterococci 
were identified by consulting a database of prophage sequences within bacterial genomes. 
Their amino acid sequences were analyzed in order to highlight both functional domains and 
possible differences with the previously described lysins. Three new lysins (plyEF, plyHH22 
and plyE613) and the previously described enterococcal lysin plyV12 were studied. Cloning 
and purification were performed using several bacterial expression vectors with and without a 
C-terminal six-histidine tag. The expression and activity of lysins were screened by different 
methods. Recombinant host bacteria (E. coli BL21) were grown in various media and lysin 
expression was induced with IPTG. Induction of plyEF, plyHH22 and plyE613 readily blocked 
the growth of E. coli recipients, suggesting that they were toxic for this particular host. Thus, 
these enzymes could not be further purified. In contrast, induction of plyV12 did not block E. 
coli growth and the enzyme could be further studied. The latter results confirm the validity of 
our protocol. Moreover, we could also confirm the rapid lytic activity of plyV12 against E. 
faecalis ATCC 29212. The reason of the toxicity of plyEF, plyHH22 and plyE613 toward E. coli 
is as yet unclear and needs to be further explored. 
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Introduction 
  
Enterococcus spp. are Gram-positive bacteria that occur singly, in pairs or as short chains, 
and are difficult to differentiate from Streptococcus spp. considering only physical 
characteristics. They were considered as group D streptococci before the introduction of 
molecular method for studying microorganisms. (1) Enterococci are able to survive and grow 
under a range of adverse environments, such as extreme temperatures (5-65°C), variations of 
pH (4.5-10.0) and high NaCl concentrations. This characteristic allows them to colonize 
numerous environmental surfaces, such as mucosal surfaces of humans and animals, soil, 
water and foodstuffs. (2) Enterococci are part of the intestinal commensal flora and are found 
in the feces of most healthy adults. The colonization of other sites, such as oral cavity and 
vagina, is less common. (3) Less than 1% of the human microbiome from healthy people 
consists of Enterococcus spp. (4) Enterococcus faecalis and Enterococcus faecium are 
opportunistic pathogens; they cause invasive infections after disruption of the commensal 
relationship with the host, particularly in elderly patients and other immunocompromised 
patients. E. faecalis is the most frequent enterococcal species associated with clinical 
infections, representing 80-90% of the isolates, followed by E. faecium that is present in 5-10% 
of cases. Enterococci can be the causative agent of various infections from relatively mild 
infections, like urinary tract infections and wound infections, to more severe infections, like 
bacteremia and endocarditis. (1) Furthermore, enterococci are a major cause of healthcare 
associated infections (HAIs), such as bloodstream infections, peritonitis (usually in mixt 
infections), catheter-associated urinary tract infections, ventilator-associated pneumonia and 
surgical site infections. The prevalence of patients infected by nosocomial pathogens is 
estimated at 6% in acute care hospital in Europe. Enterococcus spp. is the third most frequent 
pathogen causing HAIs (in 9.6% of cases) after Escherichia coli (15.9%) and Staphylococcus 
aureus (12.3%). (5) In hospital setting, contamination of fomites (such as bed rails and sheets) 
and patient skin contributes to nosocomial transmission. (6) Hygiene, disinfection and isolation 
measures have been introduced to reduce transmission of bacteria in hospitals. (7) 
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Antibiotic-resistant Enterococci are becoming increasingly prevalent due to the extensive 
use of antibiotics in both the community and in the hospitals. In addition of acquiring new 
resistance genes, such as in vancomycin-resistance (see below), enterococci have intrinsic 
resistance to a large range of antibiotics such as cephalosporins, sulphonamides and low 
concentrations of aminoglycosides. The low affinity of the penicillin binding proteins (PBP) of 
enterococci to beta-lactams makes these antibiotics poorly effective against these pathogens. 
Moreover, enterococci can acquire additional resistances to antibiotics by genetic 
modifications (acquired resistances). The resistance to beta-lactam antimicrobials uses two 
mechanisms: the production of beta-lactamase and the modification of the PBPs to further 
reduce the affinity. (8) Beta-lactamase production for antibiotic resistance in enterococci was 
for the first time discovered in E. faecalis HH22 (strain used in this study). (9) Resistance to 
aminoglycosides is more prevalent in E. faecalis and is caused by a mutation within a protein 
of the 30S ribosomal subunit, the target of this class of antibiotics. (8) Resistance to 
glycopeptides, especially to vancomycin, is more prevalent in E. faecium and is due to the 
acquisition of a whole transposon (Tn1546) carrying a set of genes (mainly vanA, vanB and 
vanC) that replace the ultimate D-alanine of the peptidoglycan precursor with a D-lactate, thus 
impeding binding of vancomycin to it. (10) (11) Vancomycin resistant enterococci (VRE) were 
observed for the first time just 15 years after the drug was put on the market. (2) The 
prevalence of aminoglycoside-resistant and glycopeptide-resistant enterococci is stabilizing or 
decreasing throughout Europe due to a careful use of these antibiotics and a better control of 
the infections. (8) The prevalence of VRE is higher in the USA because of the widespread use 
of oral vancomycin against Clostridium difficile diarrhea in US hospitals. (10) Resistance to 
antibiotics varies according to the bacterium and the hospital. It is important to know the local 
epidemiology of resistance of specific bacteria in a given hospital before beginning a therapy 
with antibiotics. In the University Hospital of Lausanne (CHUV) in 2012, the susceptibilities of 
E. faecalis to aminoglycosides and E. faecium to vancomycin reach 79% and 99%, respectively 
(Figure 1). (12) These antibiotics have to be used with parsimony to maintain a low rate of 
resistance in our country. 
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(a) Aminoglycoside resistant E. faecalis     (b) Vancomycin resistant E. faecium 
      
 
 
 
 
 
 
 
 
 
       < 1% 1% to < 5%   5% to <10%       10% to <25% 25% to <50%         ≥50% 
 
Figure 1. Proportion (in percent) of invasive enterococcal isolates resistant to aminoglycoside and 
vancomycin in Europe according to the Annual report of the European Antimicrobial Resistance 
Surveillance network (EARS-Net) 2012 (8) for the European Union and the antimicrobial resistance 
statistics from CHUV 2012 (12) for Switzerland. (a) Aminoglycoside resistant E. faecalis (mean 
percentage: 26.5%). (b) Vancomycin resistant E. faecium (mean percentage: 8.1%). In general, the 
proportion of resistance has stabilized or decreased over the last years in Europe. No data are available 
for the countries filled in black. Adapted from (8) and (12) 
 
Antibiotics start to show their limits in the treatment of infectious diseases with the emergence 
of multi-drug resistant bacteria. Moreover, pharmaceutical companies are not interested in 
developing new antibiotics as it is not financially profitable. In this context, new antimicrobials 
acting by different mechanisms are highly desired. 
  
Bacteriophages (phages) are bacterial viruses that can be found in extremely different 
environments, probably everywhere where there’s life. (13) They are the most abundant 
microorganisms on the planet and they form a heterogeneous group with numerous species 
and a large genomic diversity. (14) Bacteriophages, as obligate intracellular pathogen, need 
to invade their bacterial hosts to produce progeny virions. The phage infection process (Figure 
2) begins with the specific adsorption of the phage to a receptor on the surface of the bacterial 
host and the injection of its DNA in the host cell. Then the host vital processes are blocked in 
order to replicate the DNA and synthetize the phage structural components. Finally the progeny 
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phages are assembled and released from the host cell after lysis. Lysis is performed in non-
filamentous phages by expressing two proteins: holin and endolysin. Holins are synthesized 
at a specific time to permeabilize the cytoplasmic membrane, allowing the endolysin to be 
funneled to and interact with the peptidoglycan wall. Endolysins recognize and hydrolyze 
specific peptidoglycan bonds resulting in bacterial lysis. (15) Filamentous phages replicate 
without killing the host and are continuously extruded from bacterial cell. (16) 
 
 
 
 
 
 
    (a)                           (b)    (c)   (d) 
Figure 2. Schematic representation of the bacteriophage infection process: (a) Adsorption of the 
bacteriophage and injection of DNA in the host cell, (b) DNA replication and synthesis of phage structural 
components, (c) assembly of progeny phages, (d) bacterial cell lysis and release of progeny phages. 
Adapted from (23) 
 
Bacteriophage (phage) therapy was used to treat various infections in Western countries 
before the advent of antibiotics in the 1940s. Nevertheless, in Eastern Europe and in the former 
Soviet Union, phages continued to be used alone or in association with antibiotics. A renewed 
interest in phage therapy is re-emerging in the western scientific community; finding alternative 
treatments against multi-drug resistant bacteria became necessary. During the long history of 
phages being used as antimicrobials in Eastern Europe and in the former Soviet Union, no 
report of serious complications has been published. (17) Clinical trials have been prepared to 
assess the safety and the effectiveness of this class of anti-infectives in humans. (18) People 
increasingly moved to Eastern Europe to benefit from phage therapy. Phage cocktails (several 
phages in one preparation) are used to avoid the development of phage resistance during the 
treatment. Indeed, bacteria quickly develop resistances in presence of phages. The 
modification of surface receptors with the reduction of affinity to phage adsorption is a well-
documented mechanism. Alternatively, the presence of an already inserted prophage in the 
bacterial chromosome may impede the entry of a new phage of the same class (referred to as 
phage immunity). Many more phage resistance mechanisms are likely to be uncovered. (19)  
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Recently, researchers have shown an increased interest in bacteriolytic proteins (lysins) 
encoded by phages. (20) 
 
Lysins are peptidoglycan hydrolases that are generally greater than 25 kDA in size and its 
structure is generally composed of two functional domains: an N-terminal catalytic domain and 
a C-terminal cell wall binding domain (Figure 3). The N-terminal catalytic domain cleaves 
specific peptidoglycan bonds: N-acetyl-β-D-glucosaminidases and N-acetylmuramidases 
(glycosidases) hydrolyze glycosidic bonds in the glycan strand, endopeptidases cleave the 
cross-bridge between peptidoglycan stem peptides and N-acetylmuramoyl-L-alanine 
amidases cleave amid bond connecting the glycan moiety and the stem peptide. The C-
terminal cell wall binding domain provides the high specificity of the binding. (16) Lysins quickly 
kill Gram-positive bacteria by destabilizing the cell wall through peptidoglycan digestion. As 
mentioned, when administered therapeutically from the outside of the bacterium they are only 
active against Gram-positive bacteria, because lack an outer membrane. Lysins have specific 
properties: they rapidly kill bacteria after contact with highly conserved peptidoglycan 
substrates, they are efficient against biofilm-based infections such as infective endocarditis 
(IE), they have a synergistic lethal activity with cell-wall-active antibiotics and they are able to 
resensitize bacteria to non-susceptible antibiotics. (21) The high molecular affinity to bind their 
substrate in cell wall suggests that lysins are “one-use” enzymes that do not disengage from 
the cell wall after binding and cleavage. (22) No specific resistance mechanism to lysins have 
been discovered, likely because lysins target peptidoglycan, an essential structure for the 
bacterial viability in which mutations induce cell death. (23) Additionally, the formation of biofilm 
by bacteria does not affect the ability of lysin to kill bacteria. (24) In general, lysins have 
bactericidal activity against the bacterial host of the phages from which they were isolated. (22) 
They only kill targeted bacteria with little to no effect on the unrelated commensal flora. Some 
lysins have a broader spectrum of activity such as the enterococcal phage lysin PlyV12 with 
lytic activity not only against enterococci but also against Streptococcus agalactiae and 
Streptococcus pyogenes. (25) 
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(a) Structure 
 
 
(b) Cleavage sites 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representations of the structure and the cleavage sites of lysins. (a) The two 
functional domains of lysins. (b) Sites in the peptidoglycan sensitive to cleavage by lysins. Adapted from 
(23) 
 
Lysin therapy is being evaluated in humans to assess the safety and the pharmacokinetic 
properties of this new class of anti-infectives. (26) Lysins have already been evaluated in 
animal models of pneumonia, endocarditis and sepsis. (27) (28) (29) (30) These trials have 
shown the ability of lysins to eliminate bacteria from mucosal surface and from deeper tissues, 
including bacteria in biofilms. (23) Lysins might be used in situations where the pathogen is 
known (because they are very specific) or in combination with antibiotics. Combined use of 
these two molecules may reduce the emergence of antibiotic-resistant bacteria and enable the 
use of antibiotics for shorter durations at possibly lower doses. The lysin therapy potentially 
appears to be safe. Bacteriophage are indeed part of the normal commensal flora and humans 
are constantly in contact with lysin without discernible consequences. The use of lysin as 
therapeutics could have potential limitations. First, lysins, as protein molecules, may induce 
the production of antibodies. However, in vitro and in vivo studies have shown that lysin specific 
antibodies are not neutralizing. (31) (32) Second, lysin therapy may induce inflammatory 
Catalytic domain Cell wall targeting domain N C 
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response when the bacterial content is released after lysis. Finally, some adverse events, such 
as reaction at infusion site, may develop. It is important to determine the proper doses and 
dosing schedules of lysins to administer to humans in order to be safe and effective. 
 
The purpose of the present set or experiments was to attempt identifying new original 
phage lysins active against Enterococcus spp. in general and E. faecalis in particular. The 
methodology followed a step-by-step procedure starting with the screening of putative new 
lysins using bioinformatics means, followed by physically amplifying, cloning and expressing 
these putative lysins in E. coli and eventually testing them in lysis and killing assays against 
the target organisms. As a control, cloning purification and lysis assays were performed with a 
described anti-enterococcal lysin (namely plyV12) (25), in order to validate the overall method.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Materials and methods 
 
Bacteriophage lysins identification. Prophage lysin genes were identified initially using the 
PHage Search Tool (PHAST), a web server that identifies, annotates and displays prophage 
sequences within bacterial genomes or plasmids. (33) Then the corresponding amino acid 
sequences were deduced using the Basic Local Alignment Search Tool (BLAST) in order to 
identify functional domains (catalytic domains (CD) and cell wall binding domains (CWBD)) 
and differences with previously described lysins. (34) 
 
Cloning of plyEF, plyHH22, plyE613 and plyV12. Cloning was performed in several bacterial 
expression vectors (pET28a, pET15b and pIN-IIIA) (see Table 1). Since fusing a six-histidine 
tag to a protein greatly simplifies subsequent purification but can lead to the inactivation of the 
protein enzymatic activity, different constructs with and without a six-histidine tag were used in 
order to identify any effect of the tag on protein activity. 
PlyEF, plyE613 and plyV12 genes were synthetized and subcloned into the pUC57 plasmid 
(GenScript, Piscataway, NJ, USA). Then pUC57-plyEF, pUC57-plyE613 and pUC57-plyV12 
were transformed into E. coli DH5α (Life Technologies, Carlsbad, CA, USA) in order to store 
them. PlyHH22 was obtained from E. faecalis strain HH22 using the DNeasy Blood and Tissue 
kit (Qiagen, Valencia, CA, USA) to isolate chromosomal DNA. 
All lysin genes were PCR amplified with specific primers (Microsynth, Balgach, Switzerland), 
digested with corresponding restriction endonucleases (Promega, Madison, WI, USA) and 
ligated into corresponding bacterial expression vectors. Constructs with the plasmid pET28a 
(pET28a-plyEF, pET28a-plyHH22, pET28a-plyE613 and pET28a-plyV12) contain a C-terminal 
six-histidine tag. Constructs with the plasmids pET15b (pET15b-plyEF) and pIN-IIIA (pIN-IIIA-
plyEF, pIN-IIIA-plyHH22, pIN-IIIA-plyE613 and pIN-IIIA-plyV12) do not contain a histidine tag. 
All constructs were transformed in BL21(DE3)pLysS (E. coli BL21) chemically competent E. 
coli (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions and 
a colony PCR was achieved to determine the presence or absence of the lysin genes in the 
plasmids. Restriction digestion of recombinant plasmids was also performed to confirm the 
insertion of lysin genes in the plasmids. Finally, DNA sequencing from recombinant plasmids, 
using the universal T7 primers for pET vectors and pIN-IIIA primers for pIN-IIIA vectors, was 
performed to confirm that the lysin genes were ligated at the precise planned position within 
the plasmids and to identify potential mutations. 
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 Characteristics References 
Bacterial strains 
E. coli DH5α 
E. coli BL21(DE3)pLysS 
E. coli BL21/pET28a-plyEF 
E. coli BL21/pET28a-plyV12 
E. coli BL21/pET28a-plyHH22 
E. coli BL21/pET28a-plyE613 
E. coli BL21/pET15b-plyEF 
E. coli BL21/pIN-IIIA-plyEF 
E. coli BL21/pIN-IIIA-plyV12 
E. coli BL21/pIN-IIIA-plyHH22 
E. coli BL21/pIN-IIIA-plyE613 
E. faecalis ATCC 29212 
E. faecalis HH22 
 
Competent cells 
Expression competent cells, Camr 
BL21 transformed with pET28a-plyEF 
BL21 transformed with pET28a-plyV12 
BL21 transformed with pET28a-plyHH22 
BL21 transformed with pET28a-plyE613 
BL21 transformed with pET15b-plyEF 
BL21 transformed with pIN-IIIA-plyEF 
BL21 transformed with pIN-IIIA-plyV12 
BL21 transformed with pIN-IIIA-plyHH22 
BL21 transformed with pIN-IIIA-plyE613 
Clinical isolate from patient urine 
Unknown 
 
Life Technologies 
Life Technologies 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
ATCC 
B. Murray 
Plasmids 
pET28a 
pET15b 
pIN-IIIA 
pET28a-plyEF 
pET28a-plyV12 
pET28a-plyHH22 
pET28a-plyE613 
pET15b-plyEF 
pIN-IIIA-plyEF 
pIN-IIIA-plyV12 
pIN-IIIA-plyHH22 
pIN-IIIA-plyE613 
 
Bacterial expression vector, Kanr 
Bacterial expression vector, Ampr 
Bacterial expression vector, Ampr 
pET28a containing the plyEF gene 
pET28a containing the plyV12 gene 
pET28a containing the plyHH22 gene 
pET28a containing the plyE613 gene 
pET15b containing the plyEF gene 
pIN-IIIA containing the plyEF gene 
pIN-IIIA containing the plyV12 gene 
pIN-IIIA containing the plyHH22 gene 
pIN-IIIA containing the plyE613 gene 
 
Novagen 
Novagen 
V. Fischetti 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
Oligonucleotides 
plyEFpET28aFwNcoI  
 
plyEFpET28aRevBamH1 
 
plyV12pET28aFwNcoI 
 
 
 
5’-GGGCATGCCATGGACTACTCCCAA 
AAAGCGATTGATCTGTG-3’ 
5’-CGCGGATCCTTACGCAACATAACG 
ACGCAGACCCGAGCC-3’ 
5’-CATGCCATGGCAAGTAACATTAACA 
TGGAAACCG-3’ 
 
 
This study 
 
This study 
 
This study 
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plyV12pET28aRevXhoI 
 
plyHH22pET28aFwNcoI 
 
plyHH22pET28aRevXhoI 
 
plyE613pET28aFwNcoI 
 
plyE613pET28aRevXhoI 
 
plyEFpET15bFwNcoI 
 
plyEFpET15bRevXhoI 
 
plyEFpIN-IIIAFwXbaI 
 
plyEFpIN-IIIARevHindIII 
 
plyV12pIN-IIIAFwXbaI 
 
plyV12pIN-IIIARevBamHI 
 
plyHH22pIN-IIIAFwXbaI 
 
plyHH22pIN-IIIARevHindIII 
 
plyE613pIN-IIIAFwXbaI 
 
plyE613pIN-IIIARevHindIII 
 
T7 primer #69348-3  
T7 primer #69337-3 
pIN-IIIAFw 
pIN-IIIARev 
5’-CCGCTCGAGCTTAAATGTACCCCA 
TGC-3’ 
5’-CATGCCATGGCTTTTTTAAGAAAGG 
AGC-3’ 
5’-CCGCTCGAGCGTAGCAAATGATCC 
CCATG-3’ 
5’-CATGCCATGGGACAACGAGAAACT 
GCAAAG-3’ 
5’-CCGCTCGAGTTAATTAAAGAAACCT 
GTCCCCC-3’ 
5’-GGGCATGCCATGGACTACTCCCAA 
AAAGCGATTGATCTGTG-3’ 
5’-CCGCCGCTCGAGCGCAACATAACG 
ACGCAGACCCGAGCC-3’ 
5’-CTAGTCTAGAGGTGGAATAATGAA 
CTACTCCCAAAAAGCGATTGATCT-3’ 
5’-CCCCAAGCTTACGCAACATAACGA 
CGCAGACCCGAGCCAGCC-3’ 
5’-CTAGTCTAGAGGTGGAATAATGAG 
TAACATTAACATGGAAACCGC-3’ 
5’-CGCGGATCCTTACTTAAATGTACCC 
CATGC-3’ 
5’-CTAGTCTAGAGGTGGAATAATGCC 
TTTTTTAAGAAAGGAGCATGC-3’ 
5’-CCCAAGCTTAGCTAGCAAATGATC 
CCCATG-3’ 
5’-CTAGTCTAGAGGTGGAATAATGGG 
ACAACGAGAAACTGC-3’ 
5’-CCCAAGCTTAATTAAAGAAACCTGT 
CCCCC-3’ 
5’-TAATACGACTCACTATAGGG-3’ 
5’-GCTAGTTATTGCTCAGCGG-3’ 
5’-CACACAGGAAACAGCTATGACC-3’ 
5’-GCCATAGCCTGCAATCCATAGAG-3’ 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
This study 
 
Novagen 
Novagen 
G. Resch 
G. Resch 
 
Table 1. Bacterial strains, plasmids and oligonucleotides used in this study. Camr: chloramphenicol 
resistant, Kanr: kanamycin resistant, Ampr: ampicillin resistant, ATCC: American Type Culture Collection 
(ATCC, Manassas, Virginia, USA), restriction sites are underlined. 
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Lysin expression and activity screening. Transformed E. coli BL21 selected by colony PCR 
and restriction digestion were used in this experiment. BL21/pET28a-plyEF, BL21/pET28a-
plyHH22, BL21/pET28a-plyE613 and BL21/pET28a-plyV12 were plated onto Lysogeny Agar 
(LA) plates with kanamycin (30µg/mL), chloramphenicol (25µg/mL) and 0.4 mM isopropyl-1-
thio-β-D-galactopyranoside (IPTG) for protein synthesis induction. BL21/pET15b-plyEF, 
BL21/pIN-IIIA-plyEF, BL21/pIN-IIIA-plyHH22, BL21/pIN-IIIA-plyE613 and BL21/pIN-IIIA-
plyV12 were plated onto LA plates with ampicillin (100µg/mL), chloramphenicol (25µg/mL) and 
0.4 mM IPTG. Recombinant bacteria were also plated onto LA plates without IPTG to screen 
the effect of protein synthesis induction on bacteria. The plates were incubated overnight at 
37°C. Then the colonies were exposed to chloroform vapors to permeabilize the bacteria 
allowing the release of lysins. To this end, chloroform was poured in the lids of the petri plates 
and the dishes were placed upside down on lids during 20 minutes. The plates were dried 
under the hood during 10 minutes before 15 mL of molten soft agar containing autoclaved E. 
faecalis was poured on the colonies. The agar/bacteria suspension was prepared with an 
overnight culture of E. faecalis ATCC 29212 which was centrifuged, washed with one volume 
of NaCl 0.9% and resuspended in 0.25 volume of lysis buffer (40 mM phosphate buffer, 200 
mM NaCl, 1 mM EDTA, pH 7.4). The bacterial suspension was supplemented with agar (7.5 
g/L) and autoclaved for 15 minutes at 120°C. Before use, the agar/bacteria suspension was 
melted in a microwave and equilibrated in a water bath set to 55°C. The plates were incubated 
overnight at 37°C in order to allow the formation of clearing zones surrounding the colonies. 
(35)  
 
Lysin expression and solubility assessment. Recombinant E. coli BL21 selected by colony 
PCR and validated by DNA sequencing were used in this experiment. BL21/pET28a-plyEF, 
BL21/pET28a-plyHH22 and BL21/pET28a-plyV12 were grown overnight at 37°C and 250 
revolutions per minute (rpm) in Lysogeny Broth (LB) with kanamycin (30µg/mL) and 
chloramphenicol (25µg/mL). BL21/pET15b-plyEF, BL21/pIN-IIIA-plyEF, BL21/pIN-IIIA-
plyHH22 and BL21/pIN-IIIA-plyV12 were grown overnight in LB with ampicillin (100µg/mL) and 
chloramphenicol (25µg/mL). Then 10 mL aliquots of overnight cultures were diluted in 200 mL 
of pre-heated LB and the Erlenmeyer flasks were placed in the incubator set to 37°C and 250 
rpm. The bacterial growth was monitored by observing the increase in optical density (turbidity) 
with a spectrophotometer. At OD600nm of 0.7, 20 mL aliquots were collected in small Erlenmeyer 
flasks as non-induced controls and 0.4 mM IPTG was added to the rest of the solution in order 
to induce protein synthesis. All Erlenmeyer flasks were placed in the incubator, 10 mL aliquots 
were collected in 50 mL Falcon™ tubes (Becton Dickinson, Franklin Lakes, NJ, USA) 1, 2, 3 
and 4 hours after induction and a single 10 mL aliquot was collected at 4 hours for the non-
15 
 
induced controls. Samples were kept on ice, centrifuged, resuspended in 0.25 volume of lysis 
buffer (40 mM phosphate buffer, 200 mM NaCl, 1 mM EDTA, pH 7.4) and frozen overnight at 
-80°C. Samples were thawed and sonicated on ice three times for 20 seconds at 80% of 
maximum power using a SONOPULS HD2070 sonicator (BANDELIN electronic, Berlin, 
Germany) to form a mixture of all proteins from E. coli cytoplasm and some additional 
macromolecules, cofactors and nutrients. For each sample, a total fraction aliquot was taken 
and the rest of the sample was centrifuged at 13000 rpm during 15 minutes to collect the 
supernatant (i.e. the soluble fraction or crude extract).  
A protein gel was made to assess lysin expression and solubility. To this end, all aliquots were 
prepared according to the manufacturer’s instructions and electrophoresed on NuPAGE® Bis- 
Tris Gels (Life Technologies, Carlsbad, CA, USA). A pre-stained protein standard (Novex® 
Sharp Protein Standard, Life Technologies) was used to determine the protein sizes. 
 
Lysin antibacterial activity evaluation. A bacterial suspension was prepared with E. faecalis 
ATCC 29212. To this end, bacteria were grown overnight in Brain Heart Infusion (BHI) medium. 
Then 2 mL aliquot of the overnight culture was diluted in 150 mL of pre-heated BHI and the 
mixture was placed in the incubator set to 37°C and 250 rpm. The bacterial growth was 
followed by spectrophotometry. At OD600nm of 0.4, 40 mL aliquots were centrifuged in 50 mL 
Falcon™ tubes (7 minutes, 4000 rpm), washed with NaCl 0.9% and resuspended in 20 mL of 
lysis buffer (40 mM phosphate buffer, 200 mM NaCl, 1 mM EDTA, pH 7.4) to reach an OD600nm 
of 0.9. The bacterial suspension was placed on ice before the use. 
The bacterial suspension was diluted with the protein mixtures obtained in the previous 
experiment within a Corning® 96 well plate (Corning Incorporated, Corning, NY, USA). The 
bacterial suspension and the protein mixtures were first put separately in different columns of 
the plate; odd column’s wells were filled with 150 µL of protein mixture, even column’s wells 
were filled with 150 µL of bacterial suspension and the last odd column’s wells were filled with 
150 µL of lysis buffer, as control, to confirm that the lysis buffer has no lytic effect on bacteria. 
The content of the odd column’s wells was collected using a multichannel pipette and mixed 
with the content of the neighboring even column’s wells. The decrease in OD600nm was 
immediately monitored with EL808 absorbance microplate reader run with Gen5™ software 
(BioTek, Winooski, VT, USA) set to 37°C and 3 seconds shaking before each reads. The 
OD600nm was read every minute during 1 hour. 
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Amidase_5 superfamily SH3 
Amidase_2 superfamily 
Amidase_2 superfamily 
Results            
 
Bacteriophage lysins identification. Three different E. faecalis lysins have already been 
described and trials have shown their efficacy in killing bacteria in vitro (Figure 4). (36) PlyV12 
encoded by phage Φ1 was identified by Yoong et al. in 2004. (25) EFAL-1 encoded by phage 
EFAP-1 was described by Son et al. in 2009 (37) And ORF9 encoded by phage ΦEF24C was 
characterized by Uchiyama et al. in 2011. (38) All these lysins are active against their natural 
target E. faecalis and the related species E. faecium. PlyV12 has the broadest spectrum of 
lytic activity by acting on several streptococcal and staphylococcal strains.  
 
 
(a) PlyV12               314 
 
 
(b) EFAL-1               328     
 
 
(c) ORF9                  289 
 
Figure 4. Schematic representation of previously described lysins. (a) PlyV12 has an N-terminal 
catalytic domain with N-acetylmuramyl-L-alanine amidase activity (amidase_5 superfamily) and a C-
terminal cell wall targeting domain (SH3). (b) EFAL-1 contains a conserved N-terminal domain with N-
acetylmuramyl-L-alanine amidase activity that belongs to the amidase_2 superfamily and a C-terminal 
domain of unknown function. (c) ORF9 has a conserved N-terminal catalytic domain (amidase_2 
superfamily) and a C-terminal domain with a probable binding function. (protein sizes in amino acids)  
 
Three new lysin genes were identified from the genome of three different E. faecalis strains in 
the database regrouping prophage sequences within bacterial genomes (Figure 5). The amino 
acid sequences were deduced using bioinformatics methods. Potential functional domains (CD 
and CWBD) and differences with previously described lysins were highlighted. Two of those 
lysins have a unique structure; plyEF has a supplementary lysozyme like domain potentially 
involved in wall hydrolysis and plyE613 contains three SH3 domains potentially involved in 
binding the peptidoglycan substrate. The structure of plyHH22 has similarities with the one’s 
of plyV12, but the sequences of the CD and the CWBD are different. 
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Lysozyme like 
superfamily 
Amidase_5 
superfamily SH3 
Amidase_2 
superfamily SH3 
Amidase_5 
superfamily SH3 SH3 SH3 
 
(a) PlyEF                 406 
 
 
(b) PlyHH22           374 
 
 
(C) PlyE613               590 
 
Figure 5. Schematic representation of lysins selected for this study. (a) PlyEF is a 43 kDa protein with 
three different functional domains: a lysozyme like domain involved in the hydrolysis of beta -1, 4- linked 
polysaccharides, an amidase domain with N-acetylmuramoyl-L-alanine amidase activity and a SH3 
domain for the binding to the peptidoglycan. (b) PlyHH22 is a 41 kDa protein with two different functional 
domains: a PeptidoGlycan Recognition Protein (PGRP) that can bind and, in certain cases, hydrolyze 
peptidoglycan due to an N-acetylmuramoyl-L-alanine amidase activity (amidase_2 superfamily), and 
SH3 domain for the binding with the peptidoglycan. (c) PlyE613 is a 66 kDa protein with four functional 
domains:  an amidase domain with N-acetylmuramoyl-L-alanine amidase activity and three SH3 
domains for the binding with the peptidoglycan. (protein sizes in amino acids) 
 
Cloning of plyEF, plyHH22, plyE613 and plyV12. PlyEF gene was initially cloned in pET28a 
and pET15b using a rapid cloning protocol. However, this technique failed as no plyEF genes 
were detected in the plasmids as confirmed by DNA sequencing. The cloning protocol was 
modified; the digestion and ligation times were prolonged and pET15b was replaced by pIN-
IIIA, another plasmid without C-terminal six-histidine tag. The presence of plyEF gene in the 
plasmids was confirmed by DNA sequencing and the absence of mutations in plyEF gene was 
confirmed by comparing the sequences with ClustalW2, the multiple sequence alignment 
program for DNA. (39) Then plyHH22 and plyE613 were cloned using the same protocol. The 
insertion of lysin genes without mutations in the plasmids was confirmed by DNA sequencing. 
The positive control plyV12 was processed in parallel to confirm the validity of the cloning 
protocol. 
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Lysin expression and activity screening. Genetically modified E. coli BL21 were grown on 
two different LA plates containing specific antibiotics; one with IPTG for protein synthesis 
induction and the other without IPTG. After an overnight incubation, the colonies were 
permeabilized with chloroform vapors and overlaid with autoclaved E. faecalis ATCC 29212 
supplemented with agar.  
Recombinant E. coli BL21, obtained with the modified cloning protocol, were tested for 
confirmation of the presence of the lysin genes in the plasmids by DNA sequencing. 
BL21/pET28a-plyEF, BL21/pIN-IIIA-plyEF, BL21/pET28a-plyHH22, BL21/pIN-IIIA-plyHH22, 
BL21/pET28a-plyE613 and BL21/pIN-IIIA-plyE613 were plated onto LA plates with and without 
IPTG. After an overnight incubation, all bacteria have grown on the plates without IPTG, but 
only certain of them were found on both plain and IPTG containing plates (see Figure 6). This 
suggest already the possibility of a toxic effect of the expressed lysins. The plates were 
nevertheless overlaid with the agar/bacteria suspension, but no lysis zone surrounding the 
colonies was observed. Two types of bacteria were highlighted by DNA sequencing; those that 
have integrated an empty plasmid and that have grown on both types of plates and those that 
have integrated plasmids containing the lysin gene and that have not grown when protein 
synthesis was induced by IPTG. A second method to induce protein synthesis was tested. The 
colonies were grown overnight on LA plates without IPTG and then IPTG was vaporized on 
the plates during 1 hour using a nebulizer. The colonies were overlaid with the agar/bacteria 
suspension and again no lysis zone was observed. 
Finally, plyV12 was used as positive control in order to confirm if the cloning protocol was 
accurate. BL21/pET28a-plyV12 and BL21/pIN-IIIA-plyV12 have grown likewise on the plates 
with and without IPTG. The colonies were overlaid with the agar/bacteria suspension and lysis 
zones were observed around some of the colonies already after 1 hour of incubation. The 
presence of plyV12 gene in the bacteria surrounded by a lysis zone was confirmed by DNA 
sequencing, whereas the bacteria that was not surrounded with a lysis zone contained empty 
plasmids. 
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         11                  12                              21          22 
 
 
 
(a) PlyEF 
 
 
 
 
 
(b) PlyHH22 
 
 
 
 
 
(c) PlyE613 
 
 
 
 
 
(d) PlyV12 
 
 
 
 
Figure 6. Schematic representation of the plates used to screen lysins expression and activity. (11) LA 
plates supplemented with Kan and Cam containing BL21/pET28a-plyEF (A1), BL21/pET28a-plyHH22 
(B1), BL21/pET28a-plyE613 (C1), BL21/pET28a-plyV12 (D1) and E. coli BL21 with empty pET28a 
plasmids (A2, B2, C2 and D2). (12) LA plates supplemented with Amp containing BL21/pIN-IIIA-plyEF 
(A3), BL21/pIN-IIIA-plyHH22 (B3), BL21/pIN-IIIA-plyE613 (C3), BL21/pIN-IIIA-plyV12 (D3) and E.coli 
BL21 with empty pIN-IIIA plasmids (A4, B4, C4 and D4). (21/22) LA plates with the corresponding 
antibiotics plus IPTG, overlaid with E. faecalis ATCC 29212 supplemented with agar.  
 A1     A2               A3     A4 
 B1     B2               B3     B4 
 C1     C2               C3     C4 
 D1     D2               D3     D4  D1     D2               D3     D4 
 C1     C2               C3     C4 
 B1     B2               B3     B4 
 A1     A2               A3     A4 
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Lysin expression and solubility assessment. A protein gel was made to assess lysin 
expression and solubility. To this end, transformed E. coli BL21 harboring proper inserts were 
grown at 37°C to an OD600nm of 0.7 and induced with 0.4 mM IPTG during 1, 2, 3 or 4 hours. 
Then samples were frozen overnight and sonicated to form a mixture of all proteins from E. 
coli cytoplasm including lysins, if they are synthesized. The total and soluble fractions of 
induced cultures and the total fractions of non-induced cultures were run on NuPAGE® Bis- 
Tris Gels. 
Protein mixtures derived from BL21/pET28a-plyEF and BL21/pET15b-plyEF were run on the 
protein gel, but no supplementary band between 40 and 50 kDa (plyEF molecular weight: 43 
kDa) was observed. 
Then BL21/pET28a, BL21/pET28a-plyHH22, BL21/pIN-IIIA-plyHH22, BL21/pET28a-plyV12 
and BL21/pIN-IIIA-plyV12 were grown at 37°C to an OD600nm of 0.7 and the bacterial growth 
was followed by spectrophotometry after IPTG was added. A weak decrease in turbidity was 
observed for induced BL21/pET28a-plyHH22 whereas non-induced bacteria continued to 
proliferate reaching an OD600nm of 0.981 after 4 hours. An increase in turbidity (i.e. a bacterial 
growth) was observed for BL21/pET28a-plyV12 for both induced and non-induced fractions. 
The bacterial growth was maintained for E. coli BL21 containing empty pET28a plasmids 
(Figure 7). The protein mixtures derived from BL21/pET28a-plyHH22 were nevertheless run 
on the protein gel, but no supplementary band between 40 and 50 kDa (plyHH22 molecular 
weight: 41 kDa) was observed. Finally protein mixtures derived from BL21/pET28a-plyV12 
were tested. A supplementary band with a low intensity between 30 and 40 kDa (plyV12 
molecular weight: 34 kDa) was observed for the total induced fraction only. 
 
Figure 7. Evolution of the turbidity after protein synthesis induction with IPTG. (I) Single measure of the 
turbidity after 4 hour for the non-induced bacteria. (NI) 
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Lysin antibacterial activity evaluation. The antibacterial activity of lysins was evaluated by 
following the decrease in turbidity of a suspension of E. faecalis ATCC 29212 after the same 
volume of a mixture containing all proteins from recombinant E. coli cytoplasm was added. 
Lysis buffer and protein mixture from E. coli transformed with empty pET28a were also mixed 
with the bacterial suspension to ensure that no other molecule had antibacterial activity. 
Protein mixtures derived from BL21/pET28a-plyEF and BL21/pET28a-plyHH22 were mixed 
with the bacterial suspension. A weak decrease in turbidity of the bacterial suspension was 
observed. The decrease in turbidity was similar with the protein mixture coming from 
BL21/pET28a and with the lysis buffer. No differences were observed between the total, 
soluble and non-induced fractions.  
Protein mixtures derived from BL21/pET28a-plyV12 induce a rapid decreased in turbidity of 
the bacterial suspension with both induced and non-induced fractions. After 5 minutes (9 
minutes for the non-induced fraction) the turbidity is reduced by one half and after 35 minutes 
the turbidity reaches a plateau with an OD600nm near to 0.110. For the non-induced fraction, the 
steady-state was reached after 52 minutes with an OD600nm near to 0.120 (Figure 8). 
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(a) Comparison of the antibacterial activity of protein mixtures   
 
 
(b) Screening of the antibacterial activity of plyV12 
 
Figure 8. Protein mixtures antibacterial activity against E. faecalis ATCC 29212. (a) Comparison of the 
antibacterial activity of protein mixtures obtained from BL21/pET28a, BL21/pET28a-plyEF, 
BL21/pET28a-plyHH22 and BL21/pET28a-plyV12. The total fraction induced with IPTG during 4 hours 
was used in this experiment. (b) Screening of the antibacterial activity of plyV12. Comparison of the lytic 
activity of protein mixtures obtained from non-induced BL21/pET28a-plyV12 and from induced bacteria 
during 4 hour. The total fraction was used in this experiment. (I) stands for IPTG-induced and (NI) for 
non-induced. 
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Discussion 
 
In this study, three new prophage lysin genes were identified in the genome of different E. 
faecalis strains by screening a database of prophage sequences from published bacterial 
genomes. After a literature search, three E. faecalis lysins that have already shown their 
efficacy were identified. Three new lysin genes were identified and analyzed using 
bioinformatics methods to ensure that they were not identical to previously described lysins. 
First, the plyEF gene was cloned in pET28a and pET15b using a rapid cloning protocol. 
Recombinant bacteria selected by colony PCR and restriction digestion were plated onto LA 
plates to screen expression and activity of plyEF. All bacteria grew successfully on plates with 
and without IPTG, but no lysis zone surrounding the colonies was observed. This failure 
appeared to result from the absence of the plyEF gene in the plasmids as confirmed by DNA 
sequencing. This result was unexpected since the plyEF gene was amplified by colony PCR 
and isolated by restriction digestion. Moreover the same purified plasmids were used for the 
restriction digestion and the DNA sequencing. In view of these results, the cloning protocol 
was modified; the digestion and ligation times were prolonged to improve the insertion of the 
lysin genes in the plasmids and pET15b was replaced by pIN-IIIA. 
Second, the modified cloning protocol was run with plyEF, plyHH22 and plyE613. Recombinant 
bacteria selected by colony PCR and restriction digestion were plated onto LA plates with and 
without IPTG in order to screen the expression and activity of lysins. However only some of 
the transformed bacteria appeared to grow on the plates supplemented with IPTG and no lysis 
zone surrounding the colonies was observed. Re-analyzing the content of plasmids indicated 
that only bacteria containing “empty” plasmids were able to grow on both plain and IPTG-
induced plates. Moreover, growth curves in liquid media confirmed that the presence of plyEF, 
plyHH22 and plyE613 prevented the growth of BL21(DE3)pLysS chemically competent E. coli 
(see below). Therefore, these lysins must have some kind of toxic effect against the bacterial 
hosts and induce an interruption of the bacterial growth. A second method to induce protein 
synthesis was tested; recombinant bacteria were grown overnight and then vaporized with 
IPTG during 1 hours. The appearance of the colonies was not modified and no lysis zone 
surrounding the colonies was observed, although the presence of lysins genes was confirmed 
in all bacteria by DNA sequencing. It was not possible to screen the expression and the activity 
of these lysins, because they were probably not synthesized or synthesized in too small 
quantity to form lysis zones around the colonies. 
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An alternative method was tested to screen the expression of the lysins; protein mixtures 
derived from recombinant bacteria induced with IPTG were run on a protein gel. The bacterial 
growth was followed by spectrophotometry after the protein synthesis was induced. A 
decrease in turbidity of the solution that contains bacteria expressing plyHH22 was observed, 
whereas non-induced bacteria and bacteria containing plyV12 gene or empty plasmids 
continued to grow. The toxic activity of plyHH22 against E. coli BL21 was confirmed in this 
experiment. The weak decrease in turbidity does not allow to say if the synthesis of plyHH22 
induces an interruption of the bacterial growth or a bacterial lysis. The protein mixtures were 
nevertheless electrophoresed and no supplementary band was observed in the protein gel. 
This result was expected, since the lysins was not synthesized in sufficient quantity to form a 
supplementary band in the protein gel.   
Finally, the expression and activity of the lysins were screened by following the decrease in 
turbidity of a suspension of E. faecalis ATCC 29212 diluted with the protein mixtures obtained 
in the previous experiment. No significant decrease in turbidity (i.e. no lytic activity against E. 
faecalis) was observed. This result was expected since plyEF and plyHH22 were already not 
highlighted in the protein gel. The lysins were not synthesized or synthesized in too small 
quantity to kill bacteria, or maybe they had no lytic activity against E. faecalis ATCC 29212. 
None of these three experiments has confirmed the expression and activity of our lysins. To 
confirm the feasibility of the cloning protocol, the previously described plyV12 was tested 
following the same steps. Recombinant bacteria have grown on LA plates supplemented with 
IPTG and clearing zone surrounding the colonies were observed rapidly after the agar/bacteria 
suspension was poured on the plates. The expression of plyV12 was then confirmed with the 
protein gel, but only for the induced total fraction. This means that plyV12 was insoluble in the 
conditions of the experiment. Finally, a rapid decrease in turbidity was observed after the 
protein mixture containing plyV12 was diluted with a suspension of E. faecalis ATCC 29212. 
This confirms that it is possible to synthetize lysins with this protocol. 
In conclusion, we successfully identified three new phage lysins putatively active against 
Enterococcus spp. using bioinformatic tools. We also successfully devised a protocol to clone 
them in standard E. coli expression vectors, in which they could be expanded. The validity of 
the technique was attested by processing in parallel the described lysin plyV12, used as a 
control. Nevertheless, we failed to recover any of the three new lysins when it came to express 
them in the E. coli surrogate using IPTG induction. Nor could we recover limited amounts of 
the proteins that could carry out some anti-enterococcal lytic activity by expression leakage in 
IPTG non-induced cells. This indicates toxicity of the cloned lysins at either the transcriptional 
or translational levels. To this end we have not clue as to the responsible mechanisms. 
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However, there might be ways out to inquire about these issues. One would be to express 
truncated forms of the lysins containting either the main lytic domains or other domains, in 
order to map which part(s) of the gene is (are) responsible for E. coli toxicity. In the same 
experimental setting, if lytic domains were to be expressible alone, then they could be tested 
for their intrinsic lytic activity against target enterococci. 
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